Brivanib: a review of development (Q38048883)

27 August 2017

title

Brivanib: a review of development (English)

1 reference

27 August 2017

Tina Chou

1

1 reference

27 August 2017

Richard S Finn

series ordinal

2

1 reference

27 August 2017

language of work or name

English

0 references

publication date

1 September 2012

1 reference

27 August 2017

1 reference

27 August 2017

volume

8

1 reference

27 August 2017

issue

9

1 reference

27 August 2017

page(s)

1083-1090

1 reference

Hallmarks of Cancer: The Next Generation

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.104

Tumor angiogenesis: molecular pathways and therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.104

Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.104

FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.104

Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.104

FGFR2 as a molecular target in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.104

A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.104

Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.104

Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.104

Discovery and validation of biomarkers that respond to treatment with brivanib alaninate, a small-molecule VEGFR-2/FGFR-1 antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.104

Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast gro

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.104

The antiangiogenic activity in xenograft models of brivanib, a dual inhibitor of vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinases.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.104

Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.104

Metabolism, excretion, and pharmacokinetics of oral brivanib in patients with advanced or metastatic solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.104

A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.104

Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.104

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.104

Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.104

Design and endpoints of clinical trials in hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.104

Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.104

Features predicting sentinel lymph node positivity in Merkel cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.104

21 January 2018

Identifiers

DOI

10.2217/FON.12.104

1 reference

27 August 2017

1 reference